Mariner LLC Raises Stake in Gilead Sciences, Inc. (NASDAQ:GILD)

Mariner LLC grew its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 6.7% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 550,525 shares of the biopharmaceutical company's stock after purchasing an additional 34,541 shares during the quarter. Mariner LLC's holdings in Gilead Sciences were worth $50,850,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of GILD. Westside Investment Management Inc. lifted its position in Gilead Sciences by 3.5% during the third quarter. Westside Investment Management Inc. now owns 27,443 shares of the biopharmaceutical company's stock worth $2,249,000 after buying an additional 917 shares in the last quarter. SkyView Investment Advisors LLC increased its stake in shares of Gilead Sciences by 5.4% in the 3rd quarter. SkyView Investment Advisors LLC now owns 8,482 shares of the biopharmaceutical company's stock worth $711,000 after acquiring an additional 435 shares during the last quarter. Pine Valley Investments Ltd Liability Co purchased a new position in shares of Gilead Sciences during the 3rd quarter worth $209,000. World Investment Advisors LLC boosted its position in shares of Gilead Sciences by 33.6% during the 3rd quarter. World Investment Advisors LLC now owns 25,999 shares of the biopharmaceutical company's stock valued at $2,180,000 after acquiring an additional 6,535 shares during the last quarter. Finally, Arvest Bank Trust Division purchased a new stake in shares of Gilead Sciences in the third quarter valued at about $9,661,000. Hedge funds and other institutional investors own 83.67% of the company's stock.

Remove Ads

Wall Street Analysts Forecast Growth

Several research firms have weighed in on GILD. The Goldman Sachs Group boosted their target price on shares of Gilead Sciences from $85.00 to $96.00 and gave the company a "neutral" rating in a report on Wednesday, February 12th. Morgan Stanley raised their target price on Gilead Sciences from $123.00 to $130.00 and gave the stock an "overweight" rating in a research note on Tuesday, March 11th. Piper Sandler upped their price target on Gilead Sciences from $105.00 to $110.00 and gave the company an "overweight" rating in a research note on Wednesday, February 12th. DZ Bank upgraded shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $108.00 price objective on the stock in a report on Thursday, February 13th. Finally, Oppenheimer increased their target price on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an "outperform" rating in a research note on Tuesday, March 4th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have issued a strong buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $105.12.

Insiders Place Their Bets

In related news, CFO Andrew D. Dickinson sold 137,676 shares of the company's stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $102.22, for a total value of $14,073,240.72. Following the completion of the sale, the chief financial officer now directly owns 171,223 shares of the company's stock, valued at $17,502,415.06. This represents a 44.57 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders have sold 302,785 shares of company stock valued at $30,540,875. 0.16% of the stock is currently owned by insiders.

Gilead Sciences Stock Down 0.8 %

NASDAQ GILD traded down $0.80 during trading on Wednesday, reaching $104.88. 7,115,838 shares of the company's stock were exchanged, compared to its average volume of 7,504,431. The company has a 50 day moving average price of $108.63 and a two-hundred day moving average price of $97.11. The stock has a market cap of $130.59 billion, a P/E ratio of 283.46, a price-to-earnings-growth ratio of 0.71 and a beta of 0.32. Gilead Sciences, Inc. has a 1 year low of $62.07 and a 1 year high of $119.96. The company has a debt-to-equity ratio of 1.24, a quick ratio of 1.20 and a current ratio of 1.50.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. On average, equities research analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Friday, March 28th. Shareholders of record on Friday, March 14th were paid a $0.79 dividend. This represents a $3.16 annualized dividend and a yield of 3.01%. The ex-dividend date was Friday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.77. Gilead Sciences's dividend payout ratio is currently 854.05%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.